New drug combo offers hope for tough lung cancer
NCT ID NCT07388875
First seen Feb 05, 2026 · Last updated Apr 28, 2026 · Updated 9 times
Summary
This study tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, in 30 adults with extensive-stage small cell lung cancer that has worsened after initial treatment. The goal is to see if the combination can shrink tumors or slow the cancer's growth. Participants will receive the drugs intravenously and orally, and researchers will monitor side effects and how long the benefits last.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.